Skip to main content
Top
Published in: Osteoporosis International 8/2012

01-08-2012 | Opinion Paper

What’s in a name? What constitutes the clinical diagnosis of osteoporosis?

Authors: E. S. Siris, S. Boonen, P. J. Mitchell, J. Bilezikian, S. Silverman

Published in: Osteoporosis International | Issue 8/2012

Login to get access

Abstract

Osteoporosis is a skeletal disorder in which reductions in bone strength predispose to an increased risk for fractures. Currently, the diagnosis is officially made based exclusively on bone mineral density T-scores that are ≤−2.5 at the spine or hip. Limiting the clinical diagnosis of osteoporosis solely to a T-score-based criterion, which is the official convention in the USA, creates uncertainty about the use of the term osteoporosis to diagnose older women and men who have T-scores >−2.5, but either have already sustained low-trauma fractures or are recognized as having high fracture risk based on absolute fracture risk calculations from FRAX or other algorithms. A failure to diagnose such patients as having osteoporosis may be one component of the well-documented underdiagnosis and undertreatment of this disease which limits our ability to reduce the burden of fractures worldwide. There is a need to expand the criteria for making a clinical diagnosis and to codify these changes in order to help patients, physicians, policy makers, and payers better understand who has this disease and the elevated risk for fracture that it represents.
Literature
1.
go back to reference Klibanski A, Adams-Campbell L, Bassford T et al (2001) NIH consensus development panel on osteoporosis prevention, diagnosis and treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef Klibanski A, Adams-Campbell L, Bassford T et al (2001) NIH consensus development panel on osteoporosis prevention, diagnosis and treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef
2.
go back to reference Siris ES, Chen Y, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef Siris ES, Chen Y, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef
3.
go back to reference Schuit SCE, van der Klift M, Weel AEAM et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRef Schuit SCE, van der Klift M, Weel AEAM et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRef
4.
go back to reference Wainwright SA, Marshall LM, Ensrud KE et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787–2793PubMedCrossRef Wainwright SA, Marshall LM, Ensrud KE et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787–2793PubMedCrossRef
5.
go back to reference Kanis J (2008) Assessment of osteoporosis at the primary healthcare level. WHO Collaborating Centre, University of Sheffield, Sheffield Kanis J (2008) Assessment of osteoporosis at the primary healthcare level. WHO Collaborating Centre, University of Sheffield, Sheffield
7.
go back to reference Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCrossRef Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCrossRef
8.
go back to reference Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMedCrossRef Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMedCrossRef
9.
go back to reference Gehlbach S, Saag KG, Adachi JD et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the global longitudinal study of osteoporosis in women. J Bone Miner Res 27:645–653PubMedCrossRef Gehlbach S, Saag KG, Adachi JD et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the global longitudinal study of osteoporosis in women. J Bone Miner Res 27:645–653PubMedCrossRef
10.
go back to reference Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Rel Res 461:226–230 Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Rel Res 461:226–230
12.
go back to reference Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton LJ III (2012) The potential impact of the national osteoporosis foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23:811–820PubMedCrossRef Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton LJ III (2012) The potential impact of the national osteoporosis foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23:811–820PubMedCrossRef
13.
go back to reference Eisman J, Clapham S, Kehoe L (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian Bone Care Study. J Bone Miner Res 19:1969–1975PubMedCrossRef Eisman J, Clapham S, Kehoe L (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian Bone Care Study. J Bone Miner Res 19:1969–1975PubMedCrossRef
14.
go back to reference Marsh D, Akesson K, Beaton DE et al (2011) Coordinator based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065PubMedCrossRef Marsh D, Akesson K, Beaton DE et al (2011) Coordinator based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065PubMedCrossRef
15.
go back to reference Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef
16.
go back to reference Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef
17.
go back to reference Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
18.
go back to reference Ryder KM, Cummings SR, Palermo L et al (2008) Does a history of non-vertebral fracture identify women with osteoporosis for treatment? J Gen Intern Med 23:1177–1181PubMedCrossRef Ryder KM, Cummings SR, Palermo L et al (2008) Does a history of non-vertebral fracture identify women with osteoporosis for treatment? J Gen Intern Med 23:1177–1181PubMedCrossRef
19.
go back to reference Siris ES, Simon JA, Barton IP, McClung MR, Grauer A (2008) Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 19:681–686PubMedCrossRef Siris ES, Simon JA, Barton IP, McClung MR, Grauer A (2008) Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 19:681–686PubMedCrossRef
20.
go back to reference Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293–300PubMedCrossRef Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293–300PubMedCrossRef
21.
go back to reference McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817PubMedCrossRef McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817PubMedCrossRef
22.
go back to reference Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054PubMedCrossRef Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054PubMedCrossRef
23.
go back to reference McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. doi:10.1002/jbmr.1606 McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. doi:10.​1002/​jbmr.​1606
24.
go back to reference Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735PubMedCrossRef Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735PubMedCrossRef
25.
go back to reference Donaldson MG, Palermo L, Ensrud K, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX Score and femoral neck BMD: The fracture Intervention Trial. J Bone Miner Res. doi:10.1002/jbmr.1625 Donaldson MG, Palermo L, Ensrud K, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX Score and femoral neck BMD: The fracture Intervention Trial. J Bone Miner Res. doi:10.​1002/​jbmr.​1625
Metadata
Title
What’s in a name? What constitutes the clinical diagnosis of osteoporosis?
Authors
E. S. Siris
S. Boonen
P. J. Mitchell
J. Bilezikian
S. Silverman
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 8/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-1991-0

Other articles of this Issue 8/2012

Osteoporosis International 8/2012 Go to the issue